STAT
The temporary enforcement discretion covers six peptides an FDA advisory committee recommended in July. STAT notes there is little evidence for many of these wellness compounds.
Recap by typeshit. Full story at STAT.
A US judge turned down Novo's request to halt Lilly's Zepbound advertising while the false advertising dispute continues.
STAT
STAT's Pharmalittle notes Catherine Hanaway says Lilly broke its promise on discounted drugs to hospitals, alongside new results for a Lilly weight loss drug.
STAT notes RFK Jr. and the MAHA movement have embraced peptides, though evidence for many of these wellness compounds is thin. A July FDA panel backed all six.
AP reports agency scientists did not back the administration's effort to loosen rules on peptide drugs that remain unproven.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Beauty companies are reportedly exploring products aimed at facial volume loss in people who have lost weight on GLP-1 drugs.
Loading…